Fundraising Fox
Azitra
NYSE: AZTRFarmington, US · Founded 2014 · Delaware corporation · 5 known investors
Find your way into Azitra
Sign up to find every way you can get introduced to Azitra
- Your email: who you already know at Azitra, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Azitra team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology. The company leverages a proprietary platform combining a microbial library of approximately 1,500 bacterial strains with AI/ML-powered screening and genetic engineering technology.
Founders & leadership
Board
SR
TW
Investors · 5
Bios PartnersreportedFort Worthvia Travis Whitfill · board
How we know: board seat on SEC Form D · hartfordbusiness.com · Not right? Tell us
Connecticut InnovationsreportedNew Haven · $500K – $2M
How we know: the S-1 prospectus · hartfordbusiness.com · Not right? Tell us
KdT VenturesreportedAustin · $500K – $3Mvia Cain McClary · board
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Bayerlead
Funding
SEC filings, press & company announcements$32.1M disclosed across 6 of 8 rounds · 1900–2026
- Undisclosed amountPIPE financingMar 2026Source ↗
▶$4.3MraisedOct 2022 · 5 investors · BiotechnologyRule 506(b)
▶$4.3MraisedOct 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STELLA ROBERTSONDirector
- FRANCISCO SALVAExecutive Officer, Director
- TRAVIS WHITFILLDirector
- NAVEEN KRISHANDirector
- ANDREW MCCLARYDirector
- Offering amount
- $4.5M
- Amount sold
- $4.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Travis WhitfillDirector
- Lucio IannoneDirector
- Andrew McClaryDirector
- Stella RobertsonDirector
- Richard AndrewsExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Connecticut
- Federal exemptions
- 06b
▶$17MraisedSep 2020 · 8 investors · BiotechnologyRule 506(b)
▶$17MraisedSep 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cain McClaryDirector
- Travis WhitfillDirector
- Stella RobertsonDirector
- Lucio IannoneDirector
- Ricahrd AndrewsExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Sep 2020
- Incorporated
- Corporation, Connecticut
- Federal exemptions
- 06b
▶$4.7MraisedMar 2019 · 5 investors · BiotechnologyRule 506(b)
▶$4.7MraisedMar 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard AndrewsExecutive Officer, Director
- Stella RobertsonDirector
- Travis WhitfillDirector
- Andrew McClaryDirector
- Offering amount
- $17.3M
- Amount sold
- $4.7M
- First sale
- Feb 2019
- Incorporated
- Corporation, Connecticut, 2014
- Federal exemptions
- 06b
▶$2.1MraisedApr 2018 · 5 investors · BiotechnologyRule 506(b)
▶$2.1MraisedApr 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Travis WhitfillExecutive Officer, Director
- Richard AndrewsExecutive Officer, Director, Promoter
- Daniel WagnerDirector
- Azim MunivarDirector
- Stella RobertsonDirector
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- First sale
- Apr 2018
- Incorporated
- Corporation, Connecticut, 2014
- Federal exemptions
- 06b
▶$2.9MraisedMar 2017 · 3 investors · BiotechnologyRule 506(b)
▶$2.9MraisedMar 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Azim MunivarExecutive Officer, Director, Promoter
- Stella RobertsonDirector
- Travis WhitfillExecutive Officer, Director, Promoter
- Offering amount
- $3.7M
- Amount sold
- $2.9M
- First sale
- Mar 2017
- Incorporated
- Corporation, Connecticut, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$52.9Mvaluation at IPOJun 2023 · $5.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 6
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies working in the same space as Azitra.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2019 | $719.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Science Foundation | Phase ISTTR | 2017 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Azitra do?
- Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology. The company leverages a proprietary platform combining a microbial library of approximately 1,500 bacterial strains with AI/ML-powered screening and genetic engineering technology.
- Who are Azitra's investors?
- Azitra's investors include Bios Partners, Connecticut Innovations, KdT Ventures, Leaps by Bayer.
- How much funding has Azitra raised?
- Azitra has disclosed $32.1M raised across 6 of its 8 known rounds.
- Where is Azitra headquartered?
- Azitra is headquartered in Farmington, US.